Hypercholesteremia

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

2100%

+ 4 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

ShionogiJapan - Osaka

1 program

RosuvastatinPhase 4Small Molecule

AstellasChina - Shenyang

1 program

atorvastatinPhase 4Small Molecule2 trials

Active Trials

NCT00408382Completed50

NCT05404139Recruiting352Est. Feb 2031

Sharp TherapeuticsPA - Pittsburgh

1 program

MK-0524APhase 31 trial

Active Trials

NCT00376584Completed825Est. Jan 2007

MSDIreland - Ballydine

1 program

MK-0524APhase 3

ConceptionCA - Berkeley

1 program

LimicolN/A1 trial

Active Trials

NCT01354327Completed47Est. May 2011

AstraZenecaCAMBRIDGE, United Kingdom

1 program

Pattern of Statins Use in CataloniaN/A1 trial

Active Trials

NCT01477944Completed180,723Est. Feb 2012

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Sharp TherapeuticsMK-0524A

Astellasatorvastatin

AstraZenecaPattern of Statins Use in Catalonia

ConceptionLimicol

Clinical Trials (5)

Total enrollment: 181,997 patients across 5 trials

NCT00408382 Astellasatorvastatin

Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque

50 patients

Phase 4Completed

NCT00376584 Sharp TherapeuticsMK-0524A

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Start: Jul 2006Est. completion: Jan 2007825 patients

Phase 3Completed

NCT05404139 Astellasatorvastatin

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Start: May 2023Est. completion: Feb 2031352 patients

Phase 2Recruiting

NCT01477944 AstraZenecaPattern of Statins Use in Catalonia

Pattern of Statins Use in Catalonia

Start: Feb 2012Est. completion: Feb 2012180,723 patients

N/ACompleted

NCT01354327 ConceptionLimicol

Effects of Limicol on LDL-cholesterol

Start: Dec 2008Est. completion: May 201147 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 181,997 patients

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.